StockNews.com Begins Coverage on FibroGen (NASDAQ:FGEN)
Analysts at StockNews.com started coverage on shares of FibroGen (NASDAQ:FGEN – Get Free Report) in a report issued on Friday. The firm set a “hold” rating on the biopharmaceutical company’s stock. Separately, HC Wainwright restated a “buy” rating and set a $10.00 price target on shares of FibroGen in a research report on Thursday, February […]
Analysts at StockNews.com started coverage on shares of FibroGen (NASDAQ:FGEN – Get Free Report) in a report issued on Friday. The firm set a “hold” rating on the biopharmaceutical company’s stock. Separately, HC Wainwright restated a “buy” rating and set a $10.00 price target on shares of FibroGen in a research report on Thursday, February […]
